EHA 2021 – Curis’s renaissance continues
Results in a handful of patients raise hopes again for Curis's blood cancer project CA-4948, but it is still early days.
Pfizer reveals its PD-1 secret
The company talks up sasanlimab, whose subcutaneous delivery might challenge at least some PD-(L)1 laggards.
Who will follow Curis’s clinical validation?
As Curis clinically backs a novel oncology mechanism, several companies might review their own similarly acting projects.
SITC 2020 – embargo snafu triggers the first movers
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
